Press releases

12
Jun 2024
14:27 E.S.T.

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Read more
4
Jun 2024
15:30 E.S.T.

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Read more
29
May 2024
20:30 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Read more
28
May 2024
20:30 E.S.T.

Cellectis Reports Financial Results for First Quarter 2024

Read more
25
May 2024
02:30 E.S.T.

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Read more
6
May 2024
06:05 E.S.T.

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Read more
2
May 2024
18:49 E.S.T.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Read more
29
Apr 2024
19:05 E.S.T.

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Read more
22
Apr 2024
15:16 E.S.T.

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Read more
10
Apr 2024
14:26 E.S.T.

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US